Wall Street Set to Open Higher Friday Ahead of Consumer Sentiment, Home Sales Data
U.S. Shares Higher at Close of Trade; Dow Jones Industrial Average up 0.54%
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Changes in US stocks 丨 Aravive plummeted more than 57% before the market and will be delisted from NASDAQ
GLONGHUI, January 18 | Oncology company Aravive plummeted more than 57% to $0.046 before the market. Earlier, the company announced that it would voluntarily delist from the NASDAQ Global Select Market and deregister its common stock. The NASDAQ delisting is expected to take effect around February 8.
Aravive Shares Drop 53%, Company to Delist and Deregister Stock
Aravive Shares Sink 53% After Hours on Plans to Voluntarily Terminate Listing on Nasdaq Global Select Market
Aravive Inc. Halted, News Pending
Aravive, Inc. to Delist From The Nasdaq Stock Market
Trading Halt: Halted at 4:01:00 P.m. ET - Trading Halt: Halt News Pending
Aravive Filed U.S. Patent Application #20240009271: Methods Of Treating Metastatic Cancers Using AXL Decoy Receptors
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
Aravive (ARAV) Upgraded to Strong Buy: What Does It Mean for the Stock?
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
AMC, MMLP and ARAV Among Mid-day Movers
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Intraday Session
[BT Agency Stock Review] Biotech company Aravive's stock rating downgraded
Following the release of second-quarter earnings, Cantor Fitzgerald downgraded biotech company Aravive's rating from “overbearing” to “neutral,” and lowered its target price from $18 to 25 cents. The bank said it would end the phase 1b/ 2 clinical trial of batiraxcept unless more funding was raised.